3.98 USD
-0.01 (-0.25%)
4.0288 USD
+0.05 (+1.23%)
ChartMill assigns a Buy % Consensus number of 80% to PRME. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 6.59. This target is 65.67% above the current price.
- PRME was analyzed by 17 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about PRME.
- In the previous month the buy percentage consensus was at a similar level.
- PRME was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-23 | LifeSci Capital | Initiate | Outperform |
| 2025-11-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-11-10 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-27 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-05-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-05-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-10 | JMP Securities | Initiate | Market Outperform |
| 2024-12-03 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Initiate | Buy |
| 2024-05-16 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-05-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-23 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-04-22 | Chardan Capital | Initiate | Buy |
| 2024-04-08 | TD Cowen | Initiate | Buy |
| 2024-04-03 | Wedbush | Initiate | Outperform |
| 2024-04-02 | Wedbush | Initiate | Outperform |
| 2024-03-05 | Guggenheim | Maintains | Buy -> Buy |
PRIME MEDICINE INC / PRME FAQ
What is the price target for PRME stock?
17 analysts have analysed PRME and the average price target is 6.59 USD. This implies a price increase of 65.67% is expected in the next year compared to the current price of 3.98.
What is the consensus rating for PRIME MEDICINE INC (PRME) stock?
The consensus rating for PRIME MEDICINE INC (PRME) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.